Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2029

Conditions

Uveal MelanomaMetastatic Cutaneous Melanoma

Interventions

DRUG

Autologous Tumor Infiltrating Lymphocytes

Administered via hepatic arterial infusion (HAI)

DRUG

Melphalan

Administered via isolated hepatic perfusion

DRUG

Interleukin-2

low-dose, administered s.c.

All Listed Sponsors

lead

Vastra Gotaland Region

OTHER_GOV

NCT05903937 - Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases | Biotech Hunter | Biotech Hunter